预约演示
更新于：2025-02-06
Chlorpheniramine Maleate
马来酸氯苯那敏
更新于：2025-02-06
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H23ClN2O4 |
InChIKeyDBAKFASWICGISY-BTJKTKAUSA-N |
CAS号113-92-8 |
关联
34
项与 马来酸氯苯那敏 相关的临床试验CTRI/2024/07/071575
Effect of single dose Bilastine, desloratadine, chlorpheniramine and placebo on psychomotor functions in healthy human volunteers: A double blind placebo controlled cross over design clinical Trial - NIL
IRCT20230726058930N4
Comparison of Effect of ondansetron And Chlorpheniramine in controlling nausea in adults in emergency department
NCT05858216
First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study
100 项与 马来酸氯苯那敏 相关的临床结果
登录后查看更多信息
100 项与 马来酸氯苯那敏 相关的转化医学
登录后查看更多信息
100 项与 马来酸氯苯那敏 相关的专利（医药）
登录后查看更多信息
6,410
项与 马来酸氯苯那敏 相关的文献（医药）2024-12-16JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES
Effects of anthranilic diamide insecticides on metamorphosis in the common toad
Rhinella arenarum
(Hensel, 1867) at concentrations found in aquatic environments
Article
作者: Brodeur, Julie Céline ; Peña, Shirley Vivian Daniela Fonseca
Anthranilic diamides (AD) are a modern class of insecticides used as alternatives to pyrethroids and neonicotinoids, particularly against lepidopteran pests. Despite their widespread use and presence in surface waters, little is known regarding their effects on amphibians. The aim of this study was to examine the effects of environmentally-relevant concentrations of AD insecticides chlorantraniliprole (CHLO) and cyantraniliprole (CYAN) on metamorphosis of the toad Rhinella arenarum. Tadpoles were exposed to CHLO or CYAN at concentrations ranging from 5 and 5000 µg/L from stage 27 until metamorphosis completion. Both insecticides produced a non-monotonic acceleration of the time required for individuals to progress through development and a decrease in the proportion of individuals completing metamorphosis, although a delay in metamorphosis was also observed at 5 µg/L of CHLO. Snout-vent length and body weight of metamorphosed toads were not markedly affected by either insecticide. CHLO was more toxic than CYAN, with a lowest observed effect concentration (LOEC) for CHLO on time to metamorphosis defined as 5 µg/L compared to 5000 µg/L for CYAN. The LOEC for reduced metamorphic success defined as 50 µg/L for CHLO compared to 500 µg/L for CYAN. As most effects occurred after stage 39, when metamorphosis depends upon thyroid hormones, it is conceivable that that AD insecticides act as endocrine disruptors. These findings suggest that contamination of surface waters with CHLO and CYAN may disrupt amphibian development in the wild and warrant further research to investigate the possibility of endocrine-disruption by ADs.
2024-12-16Cureus Journal of Medical Science
Efficacy of Bilastine, Dextromethorphan, and Phenylephrine Syrup in Patients With Dry Cough: A Phase 3 Randomised Trial
Article
作者: Kodgule, Rahul ; Magar, Pankaj ; Tandon, Monika ; Shivnitwar, Sachin K ; Patil, Saiprasad ; Wu, Wen ; Pendse, Amol ; Creado, Sheldon ; Barkate, Hanmant
Background Cough in common cold is often associated with rhinorrhoea and nasal congestion, requiring treatment with a cough suppressant, decongestant, and antihistamine. Bilastine is a non-sedating antihistamine, a preferred option over sedating antihistamines. A combination of bilastine, dextromethorphan, and phenylephrine is expected to provide non-sedating treatment for cough associated with a common cold or allergy. Methods In this open-label, randomized, active-controlled, multicentre, clinical trial, adult and adolescent subjects with acute dry cough received bilastine 6.6 mg/dextromethorphan 20 mg/phenylephrine 10 mg syrup (BDP) thrice daily or Alex® syrup (chlorpheniramine maleate 4 mg/dextromethorphan 20 mg/phenylephrine 10 mg) for seven days. The objective of the study was to evaluate the efficacy and safety of a fixed-dose combination syrup of bilastine, dextromethorphan, and phenylephrine in cough relief in patients with cough associated with a common cold or allergy. Results Of 134 randomized subjects, 67 received BDP and the remaining 67 received Alex® syrup. The least-square mean (LSM) standard error (SE) change in cough severity from baseline on day 4 was 37.86 mm (2.012) in the BDP group (p < 0.001), with a mean difference between the two groups of -4.09 mm (95% CI: -9.68, 1.51). The confidence interval was within the non-inferiority (NI) limits of 30 mm, proving non-inferiority to Alex® syrup (p-value for NI < 0.001). The drowsiness score was significantly lower in the BDP group on day 2 (difference -0.46, p = 0.004), day 4 (difference -0.99, p < 0.001), and day 8 (difference -0.97, p < 0.001). No serious or severe adverse event was reported, and adverse events were comparable between the two groups. Conclusion Bilastine/dextromethorphan/phenylephrine combination syrup is efficacious, safe, non-sedating, and non-inferior to Alex® syrup in the treatment of acute dry cough due to a common cold or allergy.
2024-12-01Alzheimers & Dementia
Differential Effects of Anticholinergic Medications in Patient hiPSC‐Derived Neurons
Article
作者: Zhu, Ruowei ; Pranoto, Inez ; Gray, Shelly L ; Hui, Katherine ; Ogg, Jordan ; Young, Jessica E. ; Crane, Paul K. ; Schwarze‐Taufiq, Tiara A.
Abstract:
Background:
Anticholinergic (AC) use remains common in older adults despite evidence of safety risks, including dementia risk. Evidence from population studies suggests that dementia risk may vary by AC class. This variation might be explained by confounding by indication. In vitro models, using human neural cells where cells are directly experimentally exposed to a drug and phenotypic outcomes are measured, may address this issue. We identified classes of AC medications with and without an association with dementia based on population studies. We treated human induced pluripotent stem cell‐derived neurons (hiPSC‐Ns) with each AC medication and performed cellular assays to examine the effects on AD phenotypes.
Method:
We have generated hiPSC lines from participants in the Adult Changes in Thought Study (ACT), a longitudinal study in Seattle, WA. We differentiated hiPSC‐Ns from ACT cell lines using protocols in our laboratory. We treated neurons with different classes of AC medications: antidepressants (amitriptyline, doxepin, paroxetine), antihistamines (diphenhydramine, chlorpheniramine), bladder antimuscarinics (oxybutynin, tolterodine), and antispasmodics (atropine). As a control, we treated cells with the classic cholinergic compound carbachol. Cells were treated with two drug doses (10 uM, 50 uM) at two time points (24 hours, 48 hours). We used molecular assays to test AD‐associated cellular outcomes (neurotoxicity, synaptic gene expression and Amyloid beta [Aβ]).
Result:
We document differential effects of medications on cytotoxicity, secreted Aβ levels, and synaptic gene expression. Several drugs demonstrated dose‐dependent (doxepin, oxybutynin, paroxetine, amitriptyline) and/or time dependent (oxybutynin, paroxetine) neurotoxicity. We also observed differential effects on Aβ secretion. Oxybutynin, a bladder antimuscarinic, consistently induced an increase in the Aβ42/40 ratio, largely driven by increased secreted Aβ42. Further, all antidepressants and bladder antimuscarinics tested increased the secreted Aβ42/40 ratio at 50 uM. These findings are consistent across lines of different genetic backgrounds.
Conclusion:
Stem cell‐derived neuronal models provide a useful strategy to complement pharmacoepidemiological studies to help distinguish molecular pathways versus confounding by indication of drugs associated with dementia risk. Preliminary results suggest that different AC medications have differential effects on AD‐associated cellular outcomes that are consistent across hiPSC‐Ns derived from individuals with various genetic backgrounds, indicating a molecular effect of the drug.
100 项与 马来酸氯苯那敏 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管水肿 | 日本 | 2007-08-31 | |
| 血管性水肿 | 日本 | 1984-07-20 | |
| 湿疹 | 日本 | 1984-04-24 | |
| 皮肤疾病 | 日本 | 1984-04-24 | |
| 皮炎 | 中国 | 1981-01-01 | |
| 皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 药物性皮炎 | 中国 | 1981-01-01 | |
| 水肿 | 日本 | 1961-01-27 | |
| 瘙痒 | 日本 | 1961-01-27 | |
| 呼吸道感染 | 日本 | 1961-01-27 | |
| 过敏性鼻炎 | 日本 | 1961-01-27 | |
| 季节性过敏性鼻炎 | 日本 | 1961-01-27 | |
| 血管舒缩性鼻炎 | 日本 | 1961-01-27 | |
| 超敏反应 | 美国 | 1949-07-13 | |
| 荨麻疹 | 美国 | 1949-07-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 洪都拉斯 | 2022-07-27 | |
| 皮肤过敏 | 临床1期 | 中国 | 2019-02-19 | |
| 神经性皮炎 | 临床1期 | 中国 | 2019-02-19 | |
| 光过敏疾患 | 临床1期 | 中国 | 2019-02-19 | |
| 瘙痒（皮肤发痒） | 临床1期 | 中国 | 2019-02-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Chlorpheniramine Maleate (CPM) 10-day treatment | 醖製憲顧蓋鹽廠窪壓繭(醖願觸衊夢築膚淵壓範) = 築簾獵鹹範糧鑰醖構鬱 壓鏇餘鹽顧鏇膚繭糧遞 (鹽網選鑰襯簾夢憲衊鏇, 8.6) 更多 | - | 2023-05-21 | ||
N/A | - | 遞襯鏇淵顧膚鏇簾獵壓(製築夢廠齋齋鹹積餘鑰) = 糧構蓋憲糧窪鬱夢選鏇 顧窪艱廠鏇廠餘鹽餘淵 (範簾鑰壓廠鑰壓遞製餘 ) | 积极 | 2021-07-10 | |||
Control group | 遞襯鏇淵顧膚鏇簾獵壓(製築夢廠齋齋鹹積餘鑰) = 壓窪艱積鏇窪糧構鹽鏇 顧窪艱廠鏇廠餘鹽餘淵 (範簾鑰壓廠鑰壓遞製餘 ) | ||||||
临床2/3期 | 24 | 鏇遞鏇網願鑰鏇鹽窪衊(築製襯膚壓齋廠鹹觸憲) = 觸鹹壓糧醖構醖網壓網 膚膚簾顧顧構獵範壓夢 (襯鹹憲鏇範顧鹹簾蓋醖 ) 更多 | - | 2001-04-01 | |||
鏇遞鏇網願鑰鏇鹽窪衊(築製襯膚壓齋廠鹹觸憲) = 顧齋顧蓋繭窪衊餘夢製 膚膚簾顧顧構獵範壓夢 (襯鹹憲鏇範顧鹹簾蓋醖 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用